undamentalytics Newsletter

Koski Beverly: insider trades

Director at 2 companies we cover. 4 open-market purchases and 40 sales not made under a pre-set plan, reported from May 17, 2010 to June 6, 2017.

Would copying Koski Beverly’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. After their sales, the shares moved +19.2% against the index over 12 months on average (a negative figure means selling was the right call); 32% trailed it. None of their purchases could be priced, so there is no copy portfolio.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Koski Beverly: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 38 +3.1% +1.1% 42% 7 0.24 0.82 No reliable evidence
Sales, 12 months after the report 38 +19.2% +10.2% 32% 7 0.33 0.75 No reliable evidence
Sales, 12 months after the trade 38 +19.9% +11.5% 26% 7 0.37 0.72 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Helios Technologies, Inc. HLIO —038May 17, 2010June 6, 2017
Oragenics Inc OGEN —42August 2, 2012July 1, 2016

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 6, 2017June 2, 2017 HLIO Sale $220,050 +18.1%+7.3%+1.7%
June 2, 2017May 31, 2017 HLIO Sale $1,048,241 +9.3%+3.1%+2.7%
July 1, 2016June 30, 2016 OGEN Purchase $3,023,842 not yetnot yetnot yet
March 23, 2015March 19, 2015 HLIO Sale $1,994,837 −9.6%−19.7%−15.0%
December 16, 2014December 12, 2014 OGEN Purchase $11,581 not yetnot yetnot yet
December 15, 2014December 11, 2014 OGEN Purchase $21,742 not yetnot yetnot yet
December 1, 2014November 26, 2014 HLIO Sale $205,450 −8.9%−22.9%−24.9%
March 27, 2014March 25, 2014 OGEN Sale $20,642 not yetnot yetnot yet
March 13, 2014March 11, 2014 OGEN Sale $28,299 not yetnot yetnot yet
July 8, 2013July 5, 2013 HLIO Sale $325,000 +4.2%+1.2%+1.5%
May 30, 2013May 28, 2013 HLIO Sale $92,708 −2.8%−6.0%−3.1%
May 22, 2013May 20, 2013 HLIO Sale $653,665 −1.4%+0.7%−0.3%
March 19, 2013March 15, 2013 HLIO Sale $248,193 −8.6%+12.1%+10.4%
December 18, 2012December 14, 2012 HLIO Sale $617,418 +13.6%+22.6%+26.7%
December 12, 2012December 10, 2012 HLIO Sale $339,848 +19.0%+26.6%+20.0%
November 28, 2012November 27, 2012 HLIO Sale $256,112 +1.3%+33.3%+38.9%
September 19, 2012September 17, 2012 HLIO Sale $135,120 −1.4%+18.6%+12.1%
September 17, 2012September 13, 2012 HLIO Sale $90,764 −0.5%+15.4%+15.0%
August 23, 2012August 21, 2012 HLIO Sale $49,500 +5.5%+14.5%+15.9%
August 2, 2012July 31, 2012 OGEN Purchase $2,538,184 not yetnot yetnot yet
March 30, 2012March 28, 2012 HLIO Sale $11,300 −6.3%+10.1%+10.8%
January 3, 2012December 30, 2011 HLIO Sale $58,750 −5.9%−1.1%+3.4%
December 23, 2011December 22, 2011 HLIO Sale $19,440 −0.4%−6.8%−5.8%
November 15, 2011November 11, 2011 HLIO Sale $128,450 +20.1%−12.7%−15.4%
May 27, 2011May 25, 2011 HLIO Sale $555,678 −1.5%−23.9%−22.4%
May 16, 2011May 12, 2011 HLIO Sale $233,994 −11.0%−18.9%−19.3%
March 21, 2011March 17, 2011 HLIO Sale $173,274 +9.5%−6.1%−2.1%
March 16, 2011March 14, 2011 HLIO Sale $407,427 +8.9%−2.1%−1.4%
March 14, 2011March 11, 2011 HLIO Sale $156,046 +9.0%−2.6%+2.8%
March 14, 2011March 10, 2010 HLIO Sale $393,338 +9.0%−2.6%+33.1%
November 29, 2010November 24, 2010 HLIO Sale $451,670 +5.3%+6.1%+5.6%
November 19, 2010November 18, 2010 HLIO Sale $261,895 −2.3%+7.9%+9.5%
October 1, 2010September 29, 2010 HLIO Sale $221,269 +30.5%+10.4%+17.7%
July 2, 2010July 1, 2010 HLIO Sale $317,824 +11.0%+84.8%+80.0%
June 28, 2010June 25, 2010 HLIO Sale $19,725 +12.8%+81.8%+62.0%
June 25, 2010June 24, 2010 HLIO Sale $152,413 +5.9%+70.0%+62.7%
June 22, 2010June 21, 2010 HLIO Sale $47,643 +3.9%+61.2%+53.9%
June 17, 2010June 16, 2010 HLIO Sale $268,090 +1.0%+46.1%+46.6%
June 16, 2010June 15, 2010 HLIO Sale $262,136 +0.9%+50.6%+52.2%
June 15, 2010June 11, 2010 HLIO Sale $215,044 +0.9%+46.6%+50.0%
June 4, 2010June 2, 2010 HLIO Sale $263,246 +2.4%+61.6%+62.4%
June 2, 2010May 28, 2010 HLIO Sale $31,481 −7.4%+56.6%+63.4%
May 27, 2010May 27, 2010 HLIO Sale $213,937 −3.4%+63.4%+61.6%
May 17, 2010May 13, 2010 HLIO Sale $475,374 −10.8%+41.9%+41.1%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Koski Beverly traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.